Time of Decline in Sexual Function After External Beam Radiotherapy for Prostate Cancer

Joshua Siglin, Gregory J. Kubicek, Benjamin Leiby, Richard K Valicenti

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Purpose: Erectile dysfunction is one of the most concerning toxicities for patients in the treatment of prostate cancer. The inconsistent evaluation of sexual function (SF) and limited follow-up data have necessitated additional study to clarify the rate and timing of erectile dysfunction after external beam radiotherapy (EBRT) for prostate cancer. Methods and Materials: A total of 143 men completed baseline data on SF before treatment and at the subsequent follow-up visits. A total of 1187 validated SF inventories were analyzed from the study participants. Multiple domains of SF (sex drive, erectile function, ejaculatory function, and overall satisfaction) were analyzed for ≤8 years of follow-up. Results: The median follow-up was 4.03 years. The strongest predictor of SF after EBRT was SF before treatment. For all domains of SF, the only statistically significant decrease in function occurred in the first 24 months after EBRT. SF stabilized 2 years after treatment completion, with no statistically significant change in any area of SF >2 years after the end of EBRT. Conclusion: These data suggest that SF does not have a continuous decline after EBRT. Instead, SF decreases maximally within the first 24 months after EBRT, with no significant changes thereafter.

Original languageEnglish (US)
Pages (from-to)31-35
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume76
Issue number1
DOIs
StatePublished - Jan 2010

Keywords

  • impotence
  • prostate cancer
  • Radiotherapy
  • sexual function
  • toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Fingerprint Dive into the research topics of 'Time of Decline in Sexual Function After External Beam Radiotherapy for Prostate Cancer'. Together they form a unique fingerprint.

Cite this